{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:01:54Z","timestamp":1794506514830,"version":"4.9.1"},"reference-count":33,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Long-term efficacy and safety of the extended half-life recombinant factor IX Fc fusion protein (rFIXFc) has been established among previously treated patients with severe hemophilia B in 2 phase 3 trials (B-LONG [#NCT01027364] and Kids B-LONG [#NCT01440946]) and a long-term extension study (B-YOND [#NCT01425723]). In this study, we report post hoc analyses of pooled longitudinal data for up to 6.5 years for rFIXFc prophylaxis. In the B-LONG study, subjects \u226512 years received weekly dose-adjusted prophylaxis (WP; starting dose, 50 IU\/kg), individualized interval-adjusted prophylaxis (IP;\u00a0initially, 100 IU\/kg every 10\u00a0days), or on-demand dosing. In the Kids B-LONG study, subjects &amp;lt;12 years received 50 to 60 IU\/kg every 7\u00a0days, adjusted as needed. In the B-YOND study, subjects received WP (20-100 IU\/kg every 7\u00a0days), IP (100 IU\/kg every 8-16\u00a0days), modified prophylaxis, or on-demand dosing; switching between treatment groups was permitted. A total of 123 subjects from B-LONG and 30 from Kids B-LONG study were included, of whom 93 and 27, respectively, enrolled in the B-YOND study. The median cumulative duration of treatment was 3.63 years (range, 0.003-6.48 years) in B-LONG\/B-YOND and 2.88 years (range, 0.30-4.80 years) in Kids B-LONG\/B-YOND group. Annualized bleed rates (ABRs) remained low, annualized factor consumption remained stable, and adherence remained high throughout treatment. Low ABRs were also maintained in subjects with dosing intervals \u226514\u00a0days or with target joints at baseline. Complete resolution of evaluable target joints and no recurrence in 90.2% of baseline target joints during follow-up were observed. rFIXFc prophylaxis was associated with sustained clinical benefits, including long-term bleed prevention and target joint resolution, for severe hemophilia B.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009230","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T21:27:42Z","timestamp":1677533262000},"page":"3049-3057","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B"],"prefix":"10.1182","volume":"7","author":[{"given":"Amy D.","family":"Shapiro","sequence":"first","affiliation":[{"name":"1Indiana Hemophilia & Thrombosis Center, Inc, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9372-3184","authenticated-orcid":false,"given":"Roshni","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7830-5379","authenticated-orcid":false,"given":"Margaret V.","family":"Ragni","sequence":"additional","affiliation":[{"name":"3Department of Medicine, University of Pittsburgh, and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Chambost","sequence":"additional","affiliation":[{"name":"4Assistance Publique\u2013H\u00f4pitaux de Marseille, Hemophilia Centre, Hospital La Timone, Marseille, France"},{"name":"5Aix Marseille Universit\u00e9, INSERM, INRA, C2VN, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Mahlangu","sequence":"additional","affiliation":[{"name":"6Haemophilia Comprehensive Care Center, Faculty of Health Sciences, University of Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"7Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0145-4736","authenticated-orcid":false,"given":"Beatrice","family":"Nolan","sequence":"additional","affiliation":[{"name":"8Department of Paediatric Haematology, Children\u2019s Health Ireland at Crumlin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5938-0675","authenticated-orcid":false,"given":"Margareth C.","family":"Ozelo","sequence":"additional","affiliation":[{"name":"9Hemocentro UNICAMP, University of Campinas, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith C.","family":"Foster","sequence":"additional","affiliation":[{"name":"10Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Willemze","sequence":"additional","affiliation":[{"name":"11Sobi, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Barnowski","sequence":"additional","affiliation":[{"name":"12Sanofi, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Jain","sequence":"additional","affiliation":[{"name":"10Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bent","family":"Winding","sequence":"additional","affiliation":[{"name":"11Sobi, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dumont","sequence":"additional","affiliation":[{"name":"10Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8436-1780","authenticated-orcid":false,"given":"Stefan","family":"Lethagen","sequence":"additional","affiliation":[{"name":"11Sobi, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Barnes","sequence":"additional","affiliation":[{"name":"13Haematology Department, Royal Children\u2019s Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3394-2099","authenticated-orcid":false,"given":"K. John","family":"Pasi","sequence":"additional","affiliation":[{"name":"14Royal London Haemophilia Centre, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"issue":"1","key":"2023071016175736500_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/hae.14139","article-title":"Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)","volume":"27","author":"Shapiro","year":"2021","journal-title":"Haemophilia"},{"issue":"9","key":"2023071016175736500_bib2","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia A and B: molecular and clinical similarities and differences","volume":"104","author":"Castaman","year":"2019","journal-title":"Haematologica"},{"issue":"suppl 6","key":"2023071016175736500_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/hae.13449","article-title":"Joint disease in haemophilia: pathophysiology, pain and imaging","volume":"24","author":"van Vulpen","year":"2018","journal-title":"Haemophilia"},{"issue":"2","key":"2023071016175736500_bib4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/hae.14243","article-title":"Functional and joint evaluation in a prospective cohort of patients with severe haemophilia","volume":"27","author":"Ribeiro","year":"2021","journal-title":"Haemophilia"},{"issue":"suppl 6","key":"2023071016175736500_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"11","key":"2023071016175736500_bib6","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/bloodadvances.2019001311","article-title":"Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study","volume":"4","author":"Warren","year":"2020","journal-title":"Blood Adv"},{"issue":"26","key":"2023071016175736500_bib7","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2014-05-573055","article-title":"Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial","volume":"124","author":"Collins","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2023071016175736500_bib8","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1182\/blood-2012-05-429688","article-title":"Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients","volume":"120","author":"Santagostino","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2023071016175736500_bib9","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2011-07-367003","article-title":"Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1\/2a study in hemophilia B patients","volume":"119","author":"Shapiro","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2023071016175736500_bib10","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s11136-018-1792-9","article-title":"The impact of extended half-life versus conventional factor product on hemophilia caregiver burden","volume":"27","author":"Schwartz","year":"2018","journal-title":"Qual Life Res"},{"issue":"2","key":"2023071016175736500_bib11","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3026(16)30193-4","article-title":"Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study","volume":"4","author":"Fischer","year":"2017","journal-title":"Lancet Haematol"},{"issue":"24","key":"2023071016175736500_bib12","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023071016175736500_bib13","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1111\/hae.14036","article-title":"Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: results from the B-YOND extension study","volume":"26","author":"Pasi","year":"2020","journal-title":"Haemophilia"},{"issue":"3","key":"2023071016175736500_bib14","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1160\/TH16-05-0398","article-title":"Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B","volume":"117","author":"Pasi","year":"2017","journal-title":"Thromb Haemost"},{"issue":"6","key":"2023071016175736500_bib15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/hae.14152","article-title":"Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years","volume":"26","author":"Shapiro","year":"2020","journal-title":"Haemophilia"},{"issue":"4","key":"2023071016175736500_bib16","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/hae.14307","article-title":"Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: longitudinal follow-up in a national adult cohort","volume":"27","author":"O'Donovan","year":"2021","journal-title":"Haemophilia"},{"issue":"7","key":"2023071016175736500_bib17","doi-asserted-by":"crossref","first-page":"e12602","DOI":"10.1002\/rth2.12602","article-title":"Recombinant factor IX-Fc fusion protein in severe hemophilia B: patient-reported outcomes and health-related quality of life","volume":"5","author":"O'Donovan","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"2023071016175736500_bib18","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1111\/hae.14426","article-title":"Single centre, real-world experience of perioperative rFIXFc use in adult patients with haemophilia B undergoing major and minor surgery","volume":"27","author":"O'Donovan","year":"2021","journal-title":"Haemophilia"},{"issue":"3","key":"2023071016175736500_bib19","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/hae.13432","article-title":"Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B","volume":"24","author":"Wang","year":"2018","journal-title":"Haemophilia"},{"issue":"S2","key":"2023071016175736500_bib20","first-page":"18","article-title":"Real-world effectiveness and usage of recombinant factor IX Fc fusion protein (rFIXFc) for management of major\/minor surgeries in patents with haemophilia B (HB) in France: results from the ongoing B-SURE study","volume":"27","author":"Castet","year":"2021","journal-title":"Haemophilia"},{"issue":"5","key":"2023071016175736500_bib21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/hae.14369","article-title":"Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: a Canadian observational study of real-world outcomes","volume":"27","author":"Sun","year":"2021","journal-title":"Haemophilia"},{"issue":"S2","key":"2023071016175736500_bib22","first-page":"18","article-title":"Real-world experience of switching from SHL-rFIX to EHL-rFIXFc in moderate and severe haemophlia B patients: a retrospective analysis from two Belgian Centers","volume":"27","author":"Peerlinck","year":"2021","journal-title":"Haemophilia"},{"issue":"1","key":"2023071016175736500_bib23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/rth2.12437","article-title":"Physical activity and bleeding outcomes among people with severe hemophilia on extended half-life or conventional recombinant factors","volume":"5","author":"Shrestha","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"13","key":"2023071016175736500_bib24","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1182\/bloodadvances.2020004085","article-title":"Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B","volume":"5","author":"Nolan","year":"2021","journal-title":"Blood Adv"},{"issue":"14","key":"2023071016175736500_bib25","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"Santagostino","year":"2016","journal-title":"Blood"},{"key":"2023071016175736500_bib26","unstructured":"Rebinyn US Prescribing Information. 2020. Accessed  March 2023. https:\/\/www.novo-pi.com\/rebinyn.pdf."},{"key":"2023071016175736500_bib27","unstructured":"Idelvion SmPC. 2021. Accessed  March 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/idelvion-epar-product-information_en.pdf."},{"key":"2023071016175736500_bib28","unstructured":"Refixia SmPC. 2017. Accessed  March 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/refixia-epar-product-information_en.pdf."},{"key":"2023071016175736500_bib29","unstructured":"Idelvion US Prescribing Information. 2021. Accessed  March 2023. https:\/\/labeling.cslbehring.com\/PI\/US\/IDELVION\/EN\/IDELVION-Prescribing-Information.pdf."},{"issue":"3","key":"2023071016175736500_bib30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/hae.14300","article-title":"The function of extravascular coagulation factor IX in haemostasis","volume":"27","author":"Mann","year":"2021","journal-title":"Haemophilia"},{"issue":"1","key":"2023071016175736500_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/rth2.12163","article-title":"Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B","volume":"3","author":"Shapiro","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2023071016175736500_bib32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/hae.14455","article-title":"rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires","volume":"28","author":"Astermark","year":"2022","journal-title":"Haemophilia"},{"issue":"11","key":"2023071016175736500_bib33","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/13\/3049\/2062911\/blooda_adv-2022-009230-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/13\/3049\/2062911\/blooda_adv-2022-009230-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T16:21:07Z","timestamp":1689006067000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/13\/3049\/494712\/Post-hoc-longitudinal-assessment-of-the-efficacy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":33,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,7,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009230","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]}}}